Theravance Biopharma, Inc.
TBPHNasdaq
$16.93
↓ -0.2%Jul 17 close · end-of-day
Price
1Y↑ +45.3%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$868.2M
Enterprise Value
$473.5M
P/E
7.7
P/S
7.9
P/B
3.0
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$109.8M
Net Income (TTM)
$114.5M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
1.2%
Net Margin
104.3%
ROE
39.4%
ROIC
—
Debt / Equity
—
Net Cash
$394.7M
Return 1Y
+45.7%
Company profile
Theravance Biopharma, Inc. discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD) Its product portfolio also include Izencitinib, a gut-selective pan-janus kinase (JAK) inhibitor.
- CEO
- Rick E. Winningham
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 110
- Website
- theravance.com
Management & directors
- Miller AineSVP, DEV & HEAD OF IRE OFFICE
- Farnum RhondaSVP, COMM & MEDICAL AFFAIRS
- Grimaud Brett A.SVP, GEN COUNSEL AND SECRETARY
- Sawaf AzizSVP & CHIEF FINANCIAL OFFICER
- Winningham Rick ECHIEF EXECUTIVE OFFICER
Roles derived from SEC Form 4 filings.
Earnings
TBPH Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$17.7M↑ +15.0%
Diluted EPS-$0.10↓ -63.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $71.9M | $55.3M | $51.3M | $57.4M | $64.4M | $107.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$297.6M | -$257.8M | -$92.0M | -$56.0M | -$46.9M | -$3.6M |
| Net income | -$278.0M | -$199.4M | $872.1M | -$55.2M | -$56.4M | $105.9M |
| Diluted EPS | -$4.46 | -$2.87 | $11.85 | -$1.00 | -$1.15 | $2.06 |
| Operating cash flow | -$250.4M | -$207.9M | -$187.0M | -$27.0M | -$11.5M | $238.5M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -414.2% | -466.1% | -179.1% | -97.6% | -72.9% | -3.4% |
| Net margin | -386.9% | -360.6% | 1698.5% | -96.1% | -87.6% | 98.5% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.3M | $16.9M | $18.8M | $15.4M | $26.2M | $20.0M | $45.9M | $17.7M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$15.7M | -$10.8M | -$9.2M | -$14.4M | -$2.7M | -$6.5M | $20.0M | -$9.5M |
| Net income | -$16.5M | -$12.7M | -$15.5M | -$13.6M | $54.8M | $3.6M | $61.0M | -$4.9M |
| Diluted EPS | -$0.34 | -$0.26 | -$0.31 | -$0.27 | $1.08 | $0.07 | $1.15 | -$0.10 |
| Operating cash flow | -$4.4M | -$5.2M | -$902,000.00 | $43.0M | $208.1M | -$6.5M | -$6.1M | $73.3M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -110.2% | -64.2% | -49.1% | -93.8% | -10.4% | -32.3% | 43.6% | -53.6% |
| Net margin | -115.9% | -75.3% | -82.8% | -88.2% | 209.3% | 18.1% | 133.0% | -27.9% |
Company news
Jul 16, 2026
Jul 1, 2026
Jun 30, 2026
Jun 29, 2026
- 21d agoSector Update: Healthcare Stocks Higher Late Afternoonfinance.yahoo.com
- 21d agoZymeworks To Buy Theravance Biopharma In $929M Deal – A Look At What This Deal Means For TBPH Shareholdersstocktwits.com
- 21d agoZymeworks to Buy Theravance for Lung Disease Drug. Both Stocks Are Sliding.finance.yahoo.com
- 21d agoWhy This Biotech Stock Is Falling After a $929 Million Buyout Lifelinefinance.yahoo.com
- 21d agoZymeworks to Acquire Theravance Biopharma in $929 Million Dealfinance.yahoo.com
- 21d agoTHERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHTfinance.yahoo.com
- 21d agoZymeworks to Acquire Theravance Biopharma, Inc.finance.yahoo.com
- 21d agoTheravance, after clinical setbacks, agrees to $929M buyoutbiopharmadive.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-01 | Samaha Eli | Sale | 37,799 | $17.00 | $642,628.36 | filing |
| 2026-06-30 | Samaha Eli | Sale | 25,027 | $17.13 | $428,787.59 | filing |
| 2026-06-29 | Samaha Eli | Sale | 273,871 | $17.23 | $4.7M | filing |
| 2026-06-19 | Miller Aine· SVP, DEV & HEAD OF IRE OFFICE | Award | 18,750 | $0.00 | $0.00 | filing |
| 2026-06-15 | Farnum Rhonda· SVP, COMM & MEDICAL AFFAIRS | Sale | 6,657 | $16.39 | $109,078.94 | filing |
| 2026-06-15 | Farnum Rhonda· SVP, COMM & MEDICAL AFFAIRS | Sale | 3,329 | $16.39 | $54,562.98 | filing |
| 2026-06-15 | Farnum Rhonda· SVP, COMM & MEDICAL AFFAIRS | Sale | 3,328 | $16.38 | $54,525.29 | filing |
| 2026-06-12 | Smaldone Alsup Laurie | Award | 6,009 | $0.00 | $0.00 | filing |
| 2026-06-12 | GRAY SUSANNAH | Award | 6,009 | $0.00 | $0.00 | filing |
| 2026-06-12 | MITCHELL DEAN J | Award | 6,009 | $0.00 | $0.00 | filing |
| 2026-06-12 | O'Connor Donal | Award | 6,009 | $0.00 | $0.00 | filing |
| 2026-06-12 | PAKIANATHAN DEEPIKA | Award | 6,009 | $0.00 | $0.00 | filing |
| 2026-05-20 | Winningham Rick E· CHIEF EXECUTIVE OFFICER | Tax withholding | 20,038 | $16.55 | $331,628.90 | filing |
| 2026-05-20 | Grimaud Brett A.· SVP, GEN COUNSEL AND SECRETARY | Tax withholding | 8,829 | $16.55 | $146,119.95 | filing |
| 2026-05-20 | Sawaf Aziz· SVP & CHIEF FINANCIAL OFFICER | Tax withholding | 8,670 | $16.55 | $143,488.50 | filing |
| 2026-05-20 | Miller Aine· SVP, DEV & HEAD OF IRE OFFICE | Tax withholding | 6,827 | $16.55 | $112,986.85 | filing |
| 2026-05-20 | Farnum Rhonda· SVP, COMM & MEDICAL AFFAIRS | Tax withholding | 5,678 | $16.55 | $93,970.90 | filing |
| 2026-04-01 | Winningham Rick E· CHIEF EXECUTIVE OFFICER | Award | 75,000 | $0.00 | $0.00 | filing |
| 2026-04-01 | Sawaf Aziz· SVP & CHIEF FINANCIAL OFFICER | Award | 37,500 | $0.00 | $0.00 | filing |
| 2026-04-01 | Grimaud Brett A.· SVP, GEN COUNSEL AND SECRETARY | Award | 37,500 | $0.00 | $0.00 | filing |
| 2026-04-01 | Farnum Rhonda· SVP, COMM & MEDICAL AFFAIRS | Award | 18,750 | $0.00 | $0.00 | filing |
| 2026-03-16 | Farnum Rhonda· SVP, COMM & MEDICAL AFFAIRS | Sale | 15,534 | $14.00 | $217,476.00 | filing |
| 2026-03-16 | Farnum Rhonda· SVP, COMM & MEDICAL AFFAIRS | Sale | 7,767 | $13.92 | $108,087.90 | filing |
| 2026-03-16 | Farnum Rhonda· SVP, COMM & MEDICAL AFFAIRS | Sale | 7,766 | $13.92 | $108,073.21 | filing |
| 2026-02-20 | Winningham Rick E· CHIEF EXECUTIVE OFFICER | Tax withholding | 74,975 | $19.66 | $1.5M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.